ACT Share Price

Open 232.80 Change Price %
High 232.80 1 Day 2.20 0.95
Low 232.80 1 Week 0.00 0.00
Close 232.80 1 Month -5.45 -2.29
Volume 2 1 Year 75.80 48.28
52 Week High 266.90
52 Week Low 125.25
ACT Important Levels
Resistance 2 232.80
Resistance 1 232.80
Pivot 232.80
Support 1 232.80
Support 2 232.80
ETR Germany Most Active Stocks
CBK 11.21 3.41%
CBK 11.21 3.41%
DBK 13.94 2.73%
DBK 13.94 2.73%
EOAN 9.20 -2.75%
EOAN 9.20 -2.75%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
DTE 15.34 -2.17%
More..
ETR Germany Top Gainers Stocks
ANO 0.09 80.00%
ANO 0.09 80.00%
ANO 0.09 80.00%
S9H 0.16 45.45%
DUL 93.30 39.61%
DUL 93.30 39.61%
5M71 39.00 13.70%
VSC 5.00 12.36%
VSC 5.00 12.36%
ZSB 0.10 11.11%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
CTAA 6.62 -10.05%
TPE 4.75 -10.04%
R3Q 0.10 -9.09%
IS7 8.61 -7.22%
ITN 0.26 -7.14%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 2
As on 21st Sep 2017 ACT Share Price closed @ 232.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 212.45 & Strong Sell for SHORT-TERM with Stoploss of 240.69 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for September
1st Target up-side 239.66
2nd Target up-side 242.76
3rd Target up-side 245.85
1st Target down-side 230.84
2nd Target down-side 227.74
3rd Target down-side 224.65
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.